| NCT ID | NCT06367491 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
| Condition | Bone Metastases |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2013-10-08 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2013-10-08 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
BDMO is an Italian multicentre, observational, prospective study that collects data from all patients with bone metastases referred to each participating centre, using an on-line software 'tailor-made' for data collection.
Eligibility Criteria
Inclusion Criteria: * Radiological and/or histological diagnosis of bone metastasis from histologically established solid tumor * Males or females aged \>= 18 years * Informed consent Exclusion Criteria: * Not applicable
Contact & Investigator
Nicoletta Ranallo, MD
✉ nicoletta.ranallo@irst.emr.itFrequently Asked Questions
Who can join the NCT06367491 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bone Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06367491 currently recruiting?
Yes, NCT06367491 is actively recruiting participants. Contact the research team at nicoletta.ranallo@irst.emr.it for enrollment information.
Where is the NCT06367491 trial being conducted?
This trial is being conducted at Imola, Italy, Meldola, Italy, Gallipoli, Italy, Taormina, Italy and 11 additional locations.
Who is sponsoring the NCT06367491 clinical trial?
NCT06367491 is sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. The trial plans to enroll 800 participants.